Aprepitant (EMEND): The role of substance P in nausea and vomiting

Eric Prommer

Research output: Contribution to journalReview articlepeer-review

20 Scopus citations


Aprepitant (EMEND) is the first commercially available drug from a new class of agents, the Substance P/neurokinin NK-1 receptor antagonists. Aprepitant is indicated for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with highly emetogenic chemotherapy in adults. Its ability to antagonize the effects of Substance P has lead to greater understanding of the pathophysiology of nausea and vomiting. Its broad range of activity against a wide variety of central and peripheral emetogenic stimuli make it potentially useful in non-chemotherapy related nausea and vomiting.

Original languageEnglish (US)
Pages (from-to)31-39
Number of pages9
JournalJournal of Pain and Palliative Care Pharmacotherapy
Issue number3
StatePublished - 2005


  • Antagonist
  • Aprepitant
  • Nausea
  • Neurokinin
  • Review
  • Substance P
  • Vomiting

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Aprepitant (EMEND): The role of substance P in nausea and vomiting'. Together they form a unique fingerprint.

Cite this